5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 50

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018

Summary

According to the recently published report '5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2018'; 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. It protects cardiomyocytes against apoptosis. It plays a role in the adaptation of pulmonary arteries to chronic hypoxia and vasoconstriction.

The report '5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2018' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology, Respiratory, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Ophthalmology which include indications Drug Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Idiopathic Pulmonary Fibrosis, Psychosis, Pulmonary Arterial Hypertension, Schizophrenia, Systemic Sclerosis (Scleroderma), Alzheimer's Disease, Autism, Binge Eating Disorder, Bipolar Disorder (Manic Depression), Cirrhosis, Diarrhea, Fibrosis, Insomnia, Irritable Bowel Syndrome, Liver Fibrosis, Major Depressive Disorder, Migraine, Neuroendocrine Tumors, Non-Alcoholic Steatohepatitis (NASH), Obesity, Obsessive-Compulsive Disorder, Ocular Hypertension, Open-Angle Glaucoma, Psychiatric Disorders, Psychological Disorders, Schizoaffective Disorder and Sedation.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)

- The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics and enlists all their major and minor projects

- The report assesses 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Overview
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Companies Involved in Therapeutics Development
AnaMar AB
Astellas Pharma Inc
Neurim Pharmaceuticals Ltd
RaQualia Pharma Inc
Reviva Pharmaceuticals Inc
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Drug Profiles
AM-1476 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00310941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize HTR2B for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terguride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Dormant Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Discontinued Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Product Development Milestones
Featured News & Press Releases
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
Apr 20, 2016: RaQualia Receives a Patent Allowance for 5-HT 2B Antagonist in Korea
Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
Jun 01, 2015: RaQualia to Initiate Phase I Clinical Trial for 5-HT2B Antagonist in UK
Aug 20, 2014: RaQualia Receives a Patent Allowance for 5-HT2B Antagonist in Japan
Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5063
Jul 11, 2013: Novel antipsychotic shows early promise
Apr 09, 2013: Reviva Pharma Reports Positive Top-Line Results From Phase II Study Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
Jan 14, 2013: Reviva Pharma Completes Patient Enrollment In Phase II Trial Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AnaMar AB, H1 2018
Pipeline by Astellas Pharma Inc, H1 2018
Pipeline by Neurim Pharmaceuticals Ltd, H1 2018
Pipeline by RaQualia Pharma Inc, H1 2018
Pipeline by Reviva Pharmaceuticals Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • Global Female Condoms Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    A female condom is a birth control device that acts as a barrier to prevent sexual fluids from entering the vagina during intercourse. It protects against pregnancy and sexually transmitted infections (STIs). The online stores will be the fastest-growing segment and will continue to maintain its lead in the global market. Much of the segment's growth is due to its higher penetration rate and adoptability. Female condoms are easily accessible online and allow for useful comparison in terms......
  • Global Female Contraceptive Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 110
    Female contraceptives, also known as female birth control are methods of preventing pregnancy that primarily involve the female physiology. Female contraceptive devices account for major shares of the contraceptive pills market throughout the forecast period. The increasing adoption of female contraceptive devices will drive the growth of this product segment in the female contraceptive market. The Americas will be the major revenue contributor to the contraceptive pills market thr......
  • Global Gynecological Cancer Drugs Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 118
    The global Gynecological Cancer Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Gynecological Cancer Drugs market based on company, product type, end user and key regions. This report studies the global market size of Gynecological Cancer Drugs in key regions like North America, Europe, Asia Pacific, Central ......
  • Global Intravenous (IV) Ibuprofen Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The global Intravenous (IV) Ibuprofen market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Intravenous (IV) Ibuprofen ma......
  • Global Epoprostenol Sodium Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 102
    It is solid powder and used primarily for the treatment of pulmonary hypertension. Scope of the Report: The worldwide market for Epoprostenol Sodium is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Epoprostenol Sodium in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global Tafluprost Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 115
    It is an anti-glaucoma prostaglandin (PG) analog. Scope of the Report: The worldwide market for Tafluprost is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Tafluprost in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the......
  • Global Eszopiclone Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jan-2019        Price: US 3480 Onwards        Pages: 109
    Eszopiclone is a nonbenzodiazepine hypnotic agent. Scope of the Report: The worldwide market for Eszopiclone is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Eszopiclone in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes ......
  • Global Fibrin Sealants Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 125
    Fibrin sealant, a two-component substance consisting of thrombin and fibrinogen, is used as a hemostatic or adhesive in various surgical solutions. In clinical practice, a fibrin sealant consists of a concentrated solution of fibrinogen and Factor XIII, which combine with a solution of calcium and thrombin to form a coagulum that stimulates clotting. Beriplast P and TISSEEL are some of the commercially available fibrin sealants. The Americas accounted for 48% of the market share during th......
  • Global Consumer Healthcare Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 127
    Consumer healthcare products include trusted brands of multivitamins and iron supplements, in addition to products for allergies, personal hygiene, sleep support, alertness and cold and flu. Consumer health products do not require a written prescription from healthcare professionals but can be purchased directly from a pharmacy store. The global Consumer Healthcare market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx%......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs